NP_001121636.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
NCBI Official Full Name
ataxin-1
NCBI Official Synonym Full Names
ataxin 1
NCBI Protein Information
ataxin-1; OTTHUMP00000016065; spinocerebellar ataxia type 1 protein
UniProt Protein Name
Ataxin-1
UniProt Synonym Protein Names
Spinocerebellar ataxia type 1 protein
UniProt Synonym Gene Names
UniProt Entry Name
ATX1_HUMAN
NCBI Summary for ATXN1
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 41-81 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq]
UniProt Comments for ATXN1
ataxin-1: spinocerebellar ataxia type 1 (SCA1) protein. Expansion of CAG repeats in the SCA1 gene results in an abnormally long polyglutamine tract in the protein, causing polyglutamine-induced neurodegeneration. 14-3-3 and Akt kinase stabilize both wild-type and mutant forms of ataxin-1. The expansion of the polyglutamine tract may alter this function.
Protein type: RNA-binding; Nuclear export
Chromosomal Location of Human Ortholog: 6p23
Cellular Component: nucleoplasm; nuclear RNA export factor complex; nuclear matrix; intracellular membrane-bound organelle; cytoplasm; nucleus; nuclear inclusion body
Molecular Function: protein C-terminus binding; identical protein binding; protein binding; protein self-association; DNA binding; poly(U) binding; chromatin binding; poly(rG) binding
Biological Process: RNA processing; transcription, DNA-dependent; adult locomotory behavior; negative regulation of insulin-like growth factor receptor signaling pathway; nuclear export; negative regulation of phosphorylation; visual learning; positive regulation of transcription from RNA polymerase II promoter; negative regulation of transcription from RNA polymerase II promoter; regulation of excitatory postsynaptic membrane potential; negative regulation of transcription, DNA-dependent; alveolus development
Disease: Spinocerebellar Ataxia 1
Research Articles on ATXN1
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-ATXN1 antibody
Diseases associated with anti-ATXN1 antibody
Organs/Tissues associated with anti-ATXN1 antibody
|